drugset / Trial / NCT06863363

PEG-rhGH and Semaglutide Combination Therapy in Non-Diabetic Obese Adults

NCT06863363

Phase 4 Not yet recruiting 212 enrolled Shanghai Zhongshan Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

This study aims to evaluate the efficacy and safety of PEG-rhGH Injection combined with Semaglutide Injection versus Semaglutide Injection monotherapy in improving body composition (lean body mass, fat mass, etc.) in non-diabetic obese adults, while also analyzing changes in body weight, blood glucose, and other metabolic parameters.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject PEG-rhGH Protein / enzyme biologic 2 mg Subcutaneous
Comparator Semaglutide Peptide 2.4 mg Subcutaneous

Indications